From Guidelines to Practice: Bridging Gaps in Molecular Testing and Immunotherapy Integration for Advanced NSCLC - A QD Practic-AI Activity
Released On
September 12, 2025
Expires On
March 11, 2026
Media Type
Internet
Completion Time
75 minutes (15 minute modules)
Specialty
Hematology/Oncology
Topic(s)
Lung Cancer, Oncology
Providers/Grant Support
This activity was supported through an educational grant from Merck, Sharpe and Dohme.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credit™
- Nurses — 1.25 Nursing Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of community-based medical oncologists, nurse practitioners, physician assistants and other members of the healthcare team who treat and/or manage patients with lung cancer.
Program Overview
Enhance your expertise in applying comprehensive molecular testing and personalized immunotherapy strategies for advanced non-small cell lung cancer (NSCLC). In this adaptive, interactive Practic AI activity, your learning journey begins with a brief pre assessment that matches you to a tailored pathway—ensuring you receive content that fits your current knowledge and experience. Through real world cases, the latest evidence, and multidisciplinary perspectives, delivered by leading experts, you’ll explore how to confidently navigate complex PD L1 scenarios, select optimal first line regimens, and manage immune related adverse events.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify current guideline recommendations for molecular and biomarker testing in advanced/metastatic NSCLC and recognize common barriers to their implementation.
- Apply multidisciplinary strategies to integrate molecular testing and individualized treatment planning for advanced NSCLC.
- Apply clinical evidence and guideline-based criteria to select appropriate immunotherapy-based regimens for patients with treatment-naive advanced/metastatic NSCLC lacking actionable alterations.
- Implement patient-centered strategies to counsel on immunotherapy goals and manage immune-related adverse events in alignment with best practices.
Faculty
Co-Chairs
Daniel E. Bergsagel Chair in Medical Oncology
Professor of Medicine, University of Toronto
Adjunct Professor, IHPME, University of Toronto
Head, Division of Medical Oncology and Hematology
Princess Margaret Cancer Centre, UHN and Sinai Health System
Toronto, Canada
Associate Professor of Oncology
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Washington, DC
Faculty
Laura Alder, MD
Assistant Professor, Thoracic Medical Oncology
Deputy Medical Director
Duke Center for Brain and Spine Metastasis
Duke Cancer Institute
Duke University Health System
Durham, NC
Ticiana Leal, MD
Associate Professor
Thoracic Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, GA
Heather Wakelee, MD
Professor of Medicine
Chief of Oncology
Stanford University Medical Center
Deputy Director, Stanford Cancer Institute
Stanford, CA
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and QDcme. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
Disclosures of Conflicts of Interest
Laura Alder, MD
Consultant: FoundationOne, OncoHost, Regeneron, Eli Lilly, Genentech, MJH Life Sciences, Boehringer Ingelheim, Amgen, NuvationBio
Research: BerGenBio, ORIC Pharmaceuticals, Iambic Therapeutics
Ticiana Leal, MD
Advisory Board: Amgen, AstraZeneca,Black Diamond, Boehringer-Ingelheim,Bristol-Myers Squibb, Catalyst, Genentech, J&J, Jazz, Merck, Molecular Partners, Naterra, Novocure, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Summit Therapeutics, Takeda, Roche
Consultant: AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Catalyst, Eisai, Gilead, Genentech, J&J, Jazz Pharmaceuticals, Novartis, Novocure, Regeneron, Roche
Research:AstraZeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Jazz Pharmaceuticals, J&J, Merck, MYTHIC, Prelude, Synthekine
Natasha Leighl, MD
Research:Amgen, AstraZeneca, Boehringer Inhelheim, Bristol Meyer Squibb, Eli Lilly, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Takeda, Guardant, Neogenomics
Benjamin Levy, MD
No Conflics
Heather Wakelee, MD
Consultant: IOBiotech, Mirati, OncoC4, Beigene, GlaxoSmithKline, Bristol Meyer Squibb, Genentech/Roche, Merck, AstraZeneca
Research: AstraZeneca, Bayer, BMS, Genentech/Roche, Helsinn, Merck, SeaGen, Xcovery, Gilead
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Disclosure of Unlabeled Use
PIM requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: relias.com